Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.
You may also be interested in...
Adversity has honed a solid foundation for U.K. biotech that might be better placed to resist cyclical changes in investor sentiment than the U.S., proposes the head of the U.K biotech industry association.
Sweden's Medivir drops neuropathic pain research to focus on oncology and infectious diseases while streamlining its R&D process by partnering with India’s GVK BIO, in a bid to cut costs and raise flexibility.
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.